We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: news

Rest-Activity Rhythms as Digital Biomarkers: Predicting Relapse in Major Depressive Disorder via Actigraphy

MedXY Editorial Team•Feb 21, 2026•news
actigraphycircadian rhythmsmajor depressive disorderRelapse Prediction

The Challenge of Relapse in Major Depressive Disorder

Major depressive disorder (MDD) is a chronic and recurrent condition that imposes a staggering burden on global health systems. Despite the availability of various pharmacotherapeutic and psychotherapeutic interventions, a significant proportion of patients experience a relapsing-remitting course. Predicting these relapses remains one of the most formidable challenges in clinical psychiatry. Historically, clinicians have relied on subjective patient self-reports or intermittent clinical interviews—methods that are often hindered by recall bias and the late appearance of symptoms.

There is an urgent clinical need for objective, continuous, and non-invasive biomarkers that can signal an impending depressive episode before a full clinical relapse occurs. Recent advances in wearable technology, specifically actigraphy, have opened new avenues for digital phenotyping. By monitoring rest-activity rhythms (RARs) and sleep-wake cycles in a naturalistic environment, actigraphy provides a high-resolution window into the biological rhythms that are frequently disrupted in mood disorders.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Navigating Conflicting Clinical Trial Evidence: The FDA’s Approval Journey of Gepirone Extended Release for Major DepressionThis article critically examines the FDA’s approval of gepirone ER for major depressive disorder despite multiple negative trials, highlighting regulatory flexibility, statistical and clinical considerations, and implications for tranAug 11, 2026Ethnicity Influences Relapse-Free Survival in Immune-Mediated Thrombotic Thrombocytopenic PurpuraA French study reveals African ancestry significantly increases relapse risk in iTTP patients treated with rituximab. Key risk factors include male sex and prior relapses, with implications for personalized monitoring strategies.May 9, 2026Semaglutide Reduced Effort Discounting and Improved Motivation Signals in Major Depressive DisorderIn a 16-week randomized trial, adjunctive oral semaglutide improved effort-based decision-making in adults with major depressive disorder and overweight or obesity, suggesting a potential role for GLP-1 receptor agonism in reward-related dyMay 5, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
FT3/FT4 Ratio Emerges as a Practical Predictor of Relapse After Antithyroid Drug Withdrawal in Children
In pediatric autoimmune hyperthyroidism, a higher FT3/FT4 ratio predicted relapse after antithyroid drug withdrawal, especially when orbitopathy was present.
Apr 1, 2026
Synergistic Neuromodulation: Combined rTMS and tDCS Outperform Monotherapy in Patients with Anxious DepressionA double-blind RCT involving 240 patients reveals that combining rTMS and tDCS significantly improves remission rates and symptom reduction in Major Depressive Disorder with comorbid anxiety compared to single-modality or sham treatments, pFeb 23, 2026
Decoding Antidepressant Response: Genetic and Phenotypic Markers of Treatment Complexity and Sustained UseA large-scale retrospective cohort study identifies specific phenotypic traits and genetic markers, including the SLAMF3/LY9 locus, that predict antidepressant treatment complexity and sustained use, offering a roadmap for precision psychiaJan 31, 2026